Prenatal diagnosis and genetic counseling of a 10p11.23q11.21 duplication associated with normal phenotype

Jieping Song†, Wei Jiang†, Chengcheng Zhang† and Bo Wang*

Abstract

Background: Copy number variants (CNVs) are an important source of normal and pathogenic genome variations. Unbalanced chromosome abnormalities (UBCA) are either gains or losses or large genomic regions, but the affected person is not or only minimally clinically affected. CNVs and UBCA identified in prenatal cases need careful considerations and correct interpretation if those are harmless or harmful variants from the norm.

Case presentation: A 24-year-old, gravida 1, para 0, woman underwent amniocentesis at 17 weeks of gestation because the noninvasive prenatal testing (NIPT) results revealed a 12.4 Mb duplication from 10p11.2 to 10q11.2. GTG-banding karyotype analysis was performed on cultured amniocytes. Chromosomal microarray analysis (CMA) on uncultured amniocytes was performed.

Results: Chromosomal GTG-banding of the cultured amniocytes revealed a karyotype of 46,XX,dup(10)(p11.2q11.2). CMA detected a 12.5-Mb chromosomal duplication in the region of 10p11.23q11.21 (arr[GRCh37] 10p11.23q11.21(30,345,109_42,826,062) x 3).

Conclusion: The present report enlarges the known UBCA region 10p11.22-10q11.22 to 10p11.23-10q11.22. Also it highlights that an integration of prenatal ultrasound, NIPT, karyotype analysis, CMA and genetic counseling is helpful for the prenatal diagnosis of chromosomal deletions/duplications.

Keywords: Chromosomal microarray analysis (CMA), Noninvasive prenatal testing (NIPT), Chromosomal deletions/duplications, Prenatal diagnosis, Unbalanced chromosomal abnormalities (UBCA)

Introduction

Unbalanced chromosomal abnormalities (UBCA) were reported for euchromatic regions of many human autosomes. Carriers of UBCA are in many cases clinically healthy, and UBCA are often nothing else than cytogenetically visible copy number variants (CNVs) [1].

Noninvasive prenatal testing (NIPT) is widely used in the screening of common fetal chromosome aneuploidy [2]. Conventional karyotyping provides an overview of the entire genome and can identify structural and numerical chromosome abnormalities. Chromosomal microarray analysis (CMA) is a method using array technology to detect chromosome abnormalities spanning less than 5 Mb [3]. Because CMA does not require cell culture, samples which cannot be cultured by conventional karyotyping can be analyzed with CMA, and CMA offers faster testing result. However, conventional karyotyping is limited to detect the rearrangement with a length longer than 5 Mb, which can be detected by CMA [4] and

†Jieping Song, Wei Jiang and Chengcheng Zhang have contributed equally to this work
*Correspondence: wangbo1005@163.com

Department of Clinical Laboratory, Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei, People’s Republic of China

© The Author(s) 2022. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
CMA cannot detect balanced translocations, which can be detected by conventional karyotyping [5].

Here we report the prenatal diagnosis and genetic counseling of a novel 10p11.23q11.21 duplication in a Chinese family with normal phenotype using NIPT, chromosomal GTG-banding and CMA.

Methods

Patients and samples

In 2018, a 24-year-old, gravida 1, para 0, woman underwent amniocentesis at 17 weeks of gestation because the noninvasive prenatal testing (NIPT) results revealed 12.4 Mb duplication from 10p11.2 to 10q11.2. Her husband was 25-year old. There was no family history of birth defects or genetic diseases. GTG-banding karyotype analysis was performed on cultured amniocytes and parental blood samples. CMA on uncultured amniocytes was performed using the Affymetrix CytoScan 750 K chip, which includes 550 k non-polymorphic markers and 200 k SNP markers.

Results

Chromosomal GTG-banding revealed a karyotype of 46,XX,dup(10)(p11.2q11.2) (Fig. 1). CMA detected a 12.5-Mb chromosomal duplication in the region of 10p11.23q11.21, which is to be reported according to International System of Cytogenomic Nomenclature 2020 (ISCN 2020) [6] as arr[GRCh37] 10p11.23q11.21(30,345,109_42,826,062) × 3 (Fig. 2). Then we performed both CMA and chromosomal GTG-banding using the samples from the parents’ peripheral blood. Their karyotypes and CMA were normal. Ultrasound examination showed no dysmorphisms or intrauterine growth restriction (IUGR) in the fetus. At 24 weeks of gestation, this fetus had an estimated fetal weight of 670 g, an abdominal circumference of 19.7 cm, a head circumference of 21.9 cm, a femur length of 4.3 cm and a fetal heart rate of 145 bpm [7]. After genetic counseling, the parents decided to continue the pregnancy.

At 40 weeks of gestation, the expectant mother gave birth vaginally to a female baby. The baby’s growth parameters at birth were in the normal ranges. Apgar scores were 9/10/10. The baby received a complete physical examination and the results were normal. At 36-month checkup, the baby was developing normally (Intelligence Quotient, IQ = 110).

Discussion

According to the literature [1, 8–12] yet only several cases/families with partial trisomies of chromosome 10 within the pericentromeric region are reported, which did not show any or minimal clinical signs. Different

---

**Fig. 1** The karyotype of patient with dup(10)(p11.2q11.2)
from trisomy 10p syndrome, the pericentromeric region of chromosome 10 is proposed [11] to be a triplo-insensitive pericentromeric region.

In this study, the chromosomal duplication of 10p11.23q11.21 contains 25 genes, and these 25 genes are all triplo-insensitive genes. We report the partly dup(10) with a long-term postnatal (3 years) follow-up. To the best of our knowledge, this is the first report of an UBCA in the pericentromeric region of chromosome 10 that is not correlated with any clinical consequences, thus enlarging the yet known region 10p11.22-10q11.22 to 10p11.23-10q11.22.

Predicting the phenotypic outcome of prenatally diagnosed de novo partial dup(10) remains challenging. Important efforts have been devoted to define chromosome non-critical pericentromeric regions that tolerate duplication without phenotypic effects, a key issue in genetic counseling [8]. Unfortunately, most defined non-critical regions remain speculative at present, because available information is scarce.

Partial trisomies of chromosome 10 in the pericentromeric region were identified prenatally in several cases. A maximum of three copies of the region from 10p11.22 to 10q11.22 was observed in all cases without apparent clinical abnormalities. The imbalances were either caused by a direct duplication in one familial case or by de novo small supernumerary marker chromosomes (sSMC) [1].

On the other hand, patients with partial tetrasomy of chromosome 10 or partial trisomies of 10p (the trisomy 10p syndrome) have malformation of various organs, hypotonia, developmental delay, skeletal abnormalities and seizures [9].

During pregnancy, there were no dysmorphisms or IUGR in the fetus. At the 3-year follow-up, the baby did not have an abnormal phenotype and exhibited no evidence of developmental delay. This observation provided credence to the concept that trisomies of 10p11.23q11.21 may not contribute to abnormal phenotype. However, further study is needed to understand the expression of these 25 genes in triplicate condition and its pathogenic affect. We plan to follow this patient in order to monitor her development.

NIPT is a very efficient and accurate method for the detection of chromosome aneuploidy, especially for chromosome 13, 18 and 21. Recently, further expansion of NIPT through deeper sequencing has focused on additional screening for microdeletion and microduplications, which had also notable screening results [13].

CMA is superior to standard karyotype in detection of chromosomal microdeletion/microduplication [14].
Therefore, CMA is recommended as an additional prenatal screening item while conventional prenatal tests including blood test, ultrasonography examination and invasive prenatal diagnosis revealed abnormal findings of fetus [15].

Conclusions
Combination of prenatal ultrasound, karyotype analysis, NIPT, CMA and genetic counseling is helpful for the prenatal diagnosis of chromosomal microdeletions/ microduplications.

Abbreviations
UBCA: Unbalanced chromosome abnormalities; CNVs: Copy number variants; CMA: Chromosomal microarray analysis; NIPT: Noninvasive prenatal testing; IUGRs: Intrauterine growth restrictions.

Acknowledgements
We thanked all the participants and the families in this study for their cooperation.

Authors’ contributions
JS and CZ are responsible for clinical diagnosis and treatment. WJ is responsible for pathological examination. BW is responsible for genetic testing and thesis writing.

Funding
There was no funding available for this study.

Availability of data and materials
All relevant data and material is included in this publication.

Declarations
Ethics approval and consent to participate
The research was approved by the Ethics Committee of Maternal and Child Health Hospital of Hubei Province. All patient guardians gave informed consent to participate.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 24 April 2022 Accepted: 11 May 2022
Published online: 03 June 2022

References
1. Liehr T, Stumm M, Wegner RD, Bhatt S, Hickmann P, Patsalis PC, Meins M, Morlot S, Klaschka V, Ewers E, Hirzineer S, Miaske K, Kosyakova N, Cai WW, Cheung SW, Weise A. 10q11.2 to 10q11.1: a yet unreported region leading to unbalanced chromosomal abnormalities without phenotypic consequences. Cytogenet Genome Res. 2009;124:102–5.
2. Liang D, Cram DS, Tan H, Linpeng S, Liu Y, Sun H, Zhang Y, Tian F, Zhu H, Xu M, Wang H, Yu F, Wu L. Clinical utility of noninvasive prenatal screening for expanded chromosome disease syndromes. Genet Med. 2019;21:1998–2006.
3. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86:749–64.
4. Gekas J, van den Berg DG, Durand A, Vallee M, Wildschut HI, Buijold E, Forest JC, Rousseau F, Reinharz D. Rapid testing versus karyotyping in Down’s syndrome screening: cost-effectiveness and detection of clinically significant chromosome abnormalities. Eur J Hum Genet. 2011;19:3–9.
5. Evangelidou P, Alexandrou A, Moutafi M, Ioannides M, Antoniou P, Kounbaris G, Kalikas I, Velissariou V, Sissimani C, Patsalis PC. Implementation of high resolution whole genome array CGH in the prenatal clinical setting: advantages, challenges, and review of the literature. Biomed Res Int. 2013:2013. 346762.
6. McGowan-Jordan J, Hastings RJ, Moore S. International System of Cytogenomic Nomenclature (ISCN 2020). Switzerland: Karger; 2020.
7. Süleyman CO, Muhammed HB, Mehmet O. Predictor variables in the success of slow-release dinoprostone used for cervical ripening in intrauterine growth restriction pregnancies. J Gynecol Obstet Hum Reprod. 2020;49:101739.
8. Barranco L, Costa M, Lloveras E, Ordonez E, Maiz N, Hernando C, Villa O, Cirigliano V, Plaja A. Three-year follow-up of a prenatally ascertained apparently non-mosaic sSMC (10): delineation of a non-critical region. Cytogenet Genome Res. 2015;147:209–11.
9. Sung PL, Chang SP, Wen KC, Chang CM, Yang MJ, Chen LC, Chao KC, Huang CYF, Li YC, Lin CC. Small supernumerary marker chromosome originating from chromosome 10 associated with an apparently normal phenotype. Am J Med Genet A. 2009;149:2768–74.
10. Liehr T. Cases with heteromorphisms. http://cs-tfl.de/DB/CA/HCM/0-Start.html. Accessed 3 Mar 2022.
11. Liehr T. Benign & pathological chromosomal imbalances, 1st Edition. Microscopic and Submicroscopic Copy Number Variations (CNVs) in Genetics and Counseling. Switzerland: Academic Press; 2014.
12. Balkova I, Menten B, de Ravel T, Le Caïgnec C, Thierry C, Urbina M, Doço-Fenzy M, de Rademaeker M, Mortier G, Kooy V, van den Ende J, Devriendt K, Fryns JP, Speleman F, Verbosch JR. Subtelomeric imbalances in phenotypically normal individuals. Hum Mutat. 2007;28:958–67.
13. Chen CP, Lin SP, Chern SR, Wu PS, Chen YN, Chen SW, Lee CC, Town DD, Yang CW, Wang W. Molecular cytogenetic characterization of an inv dup(15) chromosome presenting as a small supernumerary marker chromosome associated with the inv dup(15) syndrome. Taiwan J Obstet Gynecol. 2016;55:728–32.
14. Qi H, Zhu J, Zhang S, Cai L, Wen X, Zeng W, Tang GD, Luo Y. Prenatal diagnosis of de novo monosomy 18p deletion syndrome by chromosome microarray analysis: three case reports. Medicine (Baltimore). 2019;98:e15027.
15. Committee Opinion No. 682. Microarrays and next-generation sequencing technology the use of advanced genetic diagnostic tools in obstetrics and gynecology. Obstet Gynecol. 2016;128:e262–8.